Oncolytics posts translational data from GOBLET/AWARE-1 at ASCO 2026 supporting pelareorep immune activation

ONCOLYTICS BIOTECH INC

Data from GOBLET (advanced pancreatic cancer) and AWARE-1 (early-stage breast cancer) to be presented at ASCO 2026 May 29-June 2.
In pancreatic cancer, expansion of pre-existing TIL clones correlated with tumor volume reduction; mutant KRAS-specific T-cell clones expanded.
In breast cancer, increased antiviral/immune gene expression, CXCL13 induction, and tertiary lymphoid structure formation by imaging mass cytometry.
Abstract 'Influence of pelareorep on mutant KRAS-specific blood TIL clonal expansion' (No. 2664) presented May 30, 1:30-4:30 p.m. CT.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.